search
Back to results

Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia

Primary Purpose

Anemia, Iron-Deficiency, Puerperal Disorders, Depression, Postpartum

Status
Terminated
Phase
Phase 2
Locations
Norway
Study Type
Interventional
Intervention
Ferric carboxymaltose
Ferrous sulfate tablets
Sponsored by
Norwegian University of Science and Technology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anemia, Iron-Deficiency focused on measuring Postpartum anemia, iron-deficiency

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Woman within 48 h post partum
  • Hemoglobin level equal or higher than 6.5 g/dl and equal or lower than 8.5 g/dl
  • Able to read and understand the Norwegian language
  • Signed informed consent

Exclusion Criteria:

  • Anemia not attributable to iron deficiency
  • Contraindications for any of the study drugs
  • Treatment with drugs, dietary supplements or natural remedies containing iron
  • Clinically significant condition which in the opinion of the investigator should disqualify the patient from the study
  • Assessed as requiring blood transfusion(s)

Sites / Locations

  • Department of Obstetrics, Vestre Viken Hospital Trust
  • Sykehuset Innlandet HF
  • St Olavs Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Peroral iron - ferrous sulfate tablets

Ferric carboxymaltose

Arm Description

Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily

Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.

Outcomes

Primary Outcome Measures

Haemoglobin concentration

Secondary Outcome Measures

Ferritin
Fatigue
Fatigue scale
Quality of life
SF-36
Post partum depression
Edinburgh Post Partum Depression Scale

Full Information

First Posted
June 26, 2009
Last Updated
February 15, 2012
Sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital, Sykehuset Innlandet HF, Sykehuset Buskerud HF
search

1. Study Identification

Unique Protocol Identification Number
NCT00929409
Brief Title
Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia
Official Title
A 6-week Randomised, Open Comparative, Multi-centre Study of Intravenous Ferric Carboxymaltose (Ferinject) and Oral Iron (Duroferon) for Treatment of Post Partum Anemia
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Terminated
Why Stopped
Stopped prematurely because too few patients were recruited.
Study Start Date
June 2009 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital, Sykehuset Innlandet HF, Sykehuset Buskerud HF

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
200 patients with post partum anemia will be randomised to receive either intravenous iron (intervention group) or peroral iron (control group). The hypothesis is that intravenous iron supplementation is superior to standard peroral iron.
Detailed Description
The study is a multi center phase 3 trial, comprising 3 medium sized obstetrical units in Norway. The amount of iron given to the intervention group is calculated according to the modified Ganzoni formula. The control group is given the standard regime of 200 mg ferro sulphate daily. In both groups, treatment start at inclusion, within 48 h of delivery. The sample size was based on power calculations: About 200 participants are required to detect a difference of 0.5 g/dl between the groups (with 80 % power). Randomization is performed by use of opaque envelopes. An electronic CRF is applied. Laboratory analysis are provided by a recognized Swedish biochemical laboratory. Apart from hemoglobin and the common iron parameters, the serum concentration of soluble ferritin receptors will be analyzed, as well as hepcidin levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia, Iron-Deficiency, Puerperal Disorders, Depression, Postpartum
Keywords
Postpartum anemia, iron-deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Peroral iron - ferrous sulfate tablets
Arm Type
Active Comparator
Arm Description
Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
Arm Title
Ferric carboxymaltose
Arm Type
Active Comparator
Arm Description
Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
Intervention Type
Drug
Intervention Name(s)
Ferric carboxymaltose
Other Intervention Name(s)
Ferinject
Intervention Description
Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
Intervention Type
Drug
Intervention Name(s)
Ferrous sulfate tablets
Other Intervention Name(s)
Duroferon
Intervention Description
Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
Primary Outcome Measure Information:
Title
Haemoglobin concentration
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Ferritin
Time Frame
6 weeks
Title
Fatigue
Description
Fatigue scale
Time Frame
6 weeks
Title
Quality of life
Description
SF-36
Time Frame
6 weeks
Title
Post partum depression
Description
Edinburgh Post Partum Depression Scale
Time Frame
6 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Woman within 48 h post partum Hemoglobin level equal or higher than 6.5 g/dl and equal or lower than 8.5 g/dl Able to read and understand the Norwegian language Signed informed consent Exclusion Criteria: Anemia not attributable to iron deficiency Contraindications for any of the study drugs Treatment with drugs, dietary supplements or natural remedies containing iron Clinically significant condition which in the opinion of the investigator should disqualify the patient from the study Assessed as requiring blood transfusion(s)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bjorn Backe, MD PhD
Organizational Affiliation
Norwegian University of Science and Technology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Obstetrics, Vestre Viken Hospital Trust
City
Drammen
ZIP/Postal Code
3004
Country
Norway
Facility Name
Sykehuset Innlandet HF
City
Lillehammer
ZIP/Postal Code
N 2609
Country
Norway
Facility Name
St Olavs Hospital
City
Trondheim
ZIP/Postal Code
N 7006
Country
Norway

12. IPD Sharing Statement

Learn more about this trial

Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia

We'll reach out to this number within 24 hrs